KLRA·Nasdaq·US
Kailera Therapeutics
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on obesity and related metabolic conditions. It is advancing a pipeline of GLP-1-based drug candidates, including injectable and oral therapies, through late-stage clinical development.
Recent Activity
Updated Oct 3, 2026
–Kailera Therapeutics presented new Phase 1 clinical data at the EASD 2026 Annual Meeting demonstrating flexibility in injection site for its ribupatide injection.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.